The purposes of the Clinical Oncology Program at Geisinger Medical Center are to 1) channel large numbers of patients with cancer into clinical research protocols for both cancer treatment and cancer control; 2) continue to stimulate ever-increasing quality of care for cancer patients, making full use of our large referral center; 3) provide a real stimulus to further efforts in cancer control, such as in screening, early detection, prevention, evaluation, ongoing care and rehabilitation. Aspects of the Geisinger System that favor continuation of our CCOP program include the large cancer patient population (1400 new cases/yr.), the excellent medical record system with unit patient charts, presence of all needed treatment specialist under one roof, who are full time, salaried staff, a well-working CCOP organization already in place, and a past record of successful accrual and superb data management. Our CCOP would remain multimodal, with the North Central Cancer Treatment Group as the primary research base, ECOG as a secondary affiliation, Radiation Therapy Oncology Group and a pediatric base, the Children's Cancer Study Group. This multimodal, multidisciplinary structure is a good reflection of our medical center in general, and is well suited to both our group practice and our multidisciplinary Cancer Center structure. Geisinger has always been a health care leader for this state, and is now leading the way to an expanded health care system, which includes a wide geographic spread of practice sites, different hospitals and group practices, and an HMO. The opportunity for enhanced cancer control efforts with a system like this will be given further incentive through the CCOP, with its NCI-mandated shift of emphasis to include control research. This application will demonstrate Geisinger's long-standing interest in cancer control, and cancer control research efforts. The expanding Geisinger System will give us a larger arena in which to develop and demonstrate our competence in this profoundly important effort. We welcome the challenge to move ahead and accomplish even more under the new CCOP program. We are excited to be newly associated with a cooperative group, the NCCTG, that is emerging as a leader in the cancer control research field. Relevant protocols with good science that are well suited to a rural group practice was the major attraction the NCCTG offered, and we are in a position to capitalize on it fully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035448-06
Application #
3557808
Study Section
(SRC)
Project Start
1983-09-15
Project End
1990-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Geisinger Medical Center
Department
Type
DUNS #
City
Danville
State
PA
Country
United States
Zip Code
17822
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Patel, Krishna; Foster, Nathan R; Farrell, Ann et al. (2013) Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 28:770-6
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 115 publications